NCT01289678

Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

Phase II Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Leo W. Jenkins Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment during lymphocyte recovery.

Detailed description

Upon lymphocyte recovery after myeloablative induction standard chemotherapy pulse Interleukin-2 administered

Conditions

• Acute Myelogenous Leukemia

Interventions

Type	Name	Description
DRUG	Interleukin-2	Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days

Timeline

• Start date: 2006-07-01
• Primary completion: 2016-08-31
• Completion: 2016-08-31
• First posted: 2011-02-04
• Last updated: 2019-09-12
• Results posted: 2019-09-12

Locations

1 site across 1 country: United States